The effectiveness of oral N-acetylcysteine (NAC) comparing to placebo on quality of life and respiratory profile of patients aged 6 to 18 years old with cystic fibrosis having mild to moderate pulmonary involvement

Esfahan University of Medical Sciences0 个研究点目标入组 45 人开始时间: 待定最近更新: 2021年8月30日

试验速览

暂无简介。

•1. The amount of chlorine in the sweat test is greater than or equal to 60 milliequivalents per liter or the presence of genotype containing two diagnostic mutations associated with CF and accompanied by one or more stable clinical symptoms specific to the specific phenotype of cystic fibrosis patients.
•2. patients aged range of 6 to 18 years
•3. The level of FEV1 or Forced Expiratory Volume is more than 50%
•4. Stable clinical condition in the patient and no acute infection in the patient's upper and lower respiratory system
•5. Do not aggravate the patient's pulmonary symptoms for 14 days before the patient's clinical examination

•Disability to perform and repeat spirometry test according to American Thoracic Society criteria
•use of other drugs out of the common treatment protocol that is effective on the disease.
•Having possible history of underlying cardiovascular, renal, hepatic and biliary tract diseases

发起方